Management of methicillin-resistant Staphylococcus aureus bacteremia

Clinical Infectious Diseases

Volumn 46, Issue SUPPL. 5, 2008, Pages

  Cosgrove, Sara E ^a,c   Fowler Jr , Vance G ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; ORITAVANCIN; OXACILLIN; PENICILLIN G; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEVICE REMOVAL; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENDOCARDITIS; ERYTHEMA MULTIFORME; HUMAN; INFLAMMATION; INTRAVENOUS CATHETER; LACTIC ACIDOSIS; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OPTIC NEURITIS; PAIN; PNEUMONIA; POLYNEUROPATHY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SALVAGE THERAPY; SEROTONIN SYNDROME; SIDE EFFECT; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

BACTEREMIA; ENDOCARDITIS, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 44149116511     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/533595     Document Type: Article

References (72)

1. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006; 333:281-4.
2. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012-21.
3. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
4. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066-72.
5. Malanoski GJ, Samore MH, Pefanis A, Karchmer AW. Staphylococcus aureus catheter-associated bacteremia: minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med 1995; 155:1161-6.
6. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894-9.
7. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16:567-73.
8. Ringberg H, Thoren A, Lilja B. Metastatic complications of Staphylococcus aureus septicemia: to seek is to find. Infection 2000; 28:132-6.
9. Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997; 30:1072-8.
10. Fowler VG Jr, Sanders LL, Kong LK, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999; 28:106-14.
11. Roder BL, Wandall DA, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl VT. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462-9.
12. Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005; 14:23-8.
13. Abraham J, Mansour C, Veledar E, Khan B, Lerakis S. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S. aureus and methicillin-resistant S. aureus bacteremia. Am Heart J 2004; 147:536-9.
14. Reynolds HR, Jagen MA, Tunick PA, Kronzon I. Sensitivity of transthoracic versus transesophageal echocardiography for the detection of native valve vegetations in the modern era. J Am Soc Echocardiogr 2003; 16:67-70.
15. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478-86.
16. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029-33.
17. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis - diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association. Circulation 2005; 111:e394-434 (errata: Circulation 2005; 112:2373, Circulation 2007; 115:e408, and Circulation 2007; 116: e547).
18. D'Agostino RS, Miller DC, Stinson EB, et al. Valve replacement in patients with native valve endocarditis: what really determines operative outcome? Ann Thorac Surg 1985; 40:429-38.
19. Mullany CJ, McIsaacs AI, Rowe MH, Hale GS. The surgical treatment of infective endocarditis. World J Surg 1989; 13:132-6.
20. John MD, Hibberd PL, Karchmer AW, Sleeper LA, Calderwood SB. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998; 26:1302-9.
21. Bishara J, Leibovici L, Gartman-Israel D, et al. Long-term outcome of infective endocarditis: the impact of early surgical intervention. Clin Infect Dis 2001; 33:1636-43.
22. Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993; 119:304-11.
23. Wilson R, Hamburger M. Fifteen years' experience with Staphylococcus septicemia in a large city hospital: analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am J Med 1957; 22:437-57.
24. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75-82.
25. Boucher H, Corey G, Filler S, et al. Appropriateness of two-week therapy for catheter-related (cath-rel) S. aureus bacteremia (SAB) [abstract L-1204]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
26. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267-84.
27. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
28. Sterile vancomycin hydrochloride, USP [package insert]. Schaumberg, IL: Abraxis Pharmaceutical Products, 2006.
29. Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals, 2007.
30. Zyvox (linezolid) [package insert]. New York, NY: Pharmacia & Upjohn, Division of Pfizer, 2007.
31. Synercid (quinupristin and dalfopristin) for injection [package insert]. Bristol, TN: Monarch Pharmaceuticals, 2003.
32. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-8.
33. Bactrim (sulfamethoxazole and trimethoprim tablets) [package insert]. Nutley, NJ: Roche Pharmaceuticals, 2002.
34. Cleocin (clindamycin) for injection [package insert]. Bedford, OH: Ben Venue Laboratories, 2004.
35. Tygacil (tigecycline) for injection [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, 2006.
36. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-31.
37. Gentry CA, Rodvold KA, Novak RM, Hershow RC, Naderer OJ. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17:990-7.
38. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9.
39. Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 2005; 37:572-8.
40. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-6.
41. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-80.
42. Fowler VG Jr, Boucher HW, Corey R, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
43. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51.
44. Khosrovaneh A, Riederer K, Saeed S, et al. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2004; 38:1328-30.
45. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
46. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcusaureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
47. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 mg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006; 28:1208-16.
48. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55.
49. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin in the management of native valve Staphylococcus aureus endocarditis [abstract L-610]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
50. Simon GL, Smith RH, Sande MA. Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases. Rev Infect Dis 1983; 5(Suppl 3):S507-8.
51. Abrams B, Sklaver A, Hoffman T, Greenman R. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979; 90:789-91.
52. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982; 97:496-503.
53. New drug application 21-572/supplement 008, Cubicin (daptomycin for injection): sponsor's background package for Anti-Infective Drugs Advisory Committee meeting schedule for March 6, 2006. Report NDA 21-572/S 008. Lexington, MA: Cubist Pharmaceuticals, 2006:1-92.
54. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245-9.
55. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 2006; 35:207-11.
56. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149-52.
57. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-90.
58. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521-8.
59. Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003; 22:372-3.
60. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35:1018-20.
61. Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels. Clin Infect Dis 2003; 36:675-6.
62. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56:923-9.
63. US Food and Drug Administration. Linezolid (marketed as Zyvox) information: FDA alert. Available at: http://www.fda.gov/cder/drug/infopage/ linezolid/default.htm. Accessed 12 May 2007.
64. Tack KJ, Wilcox MH, Bouza E, et al. Linezolid vs. vancomycin or oxacillin/dicloxacillin for the treatment of catheter-related bloodstream infection [abstract K1748]. In: Programs and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007.
65. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775-84.
66. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001; 32:e83-6.
67. Kaka AS, Rueda AM, Shelburne SA III, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58:680-3.
68. Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60:419-25.
69. Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006; 6:486-90.
70. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374-80.
71. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601-7.
72. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs 2007; 16:347-57.